Lv52
1540 积分 2021-03-29 加入
CMC Regulatory Considerations for Antibody-Drug Conjugates
29天前
已完结
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
1个月前
已完结
Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy
2个月前
已完结
Nonoperative Management of Mismatch Repair–Deficient Tumors
2个月前
已完结
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
2个月前
已完结
Characterization of Anti-CD3 Antibodies in Clinically Available Bispecific T Cell Engagers
2个月前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
2个月前
已完结
皖公网安备34019202002308
